References
1. Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M, Babazadeh
A, Yeganeh B, et al. Clinical and laboratory findings from patients with
COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study.
Rom J Intern Med. 2020 1;58(3):161-167.
2. Afshar ZM, Ebrahimpour S, Javanian M, Vasigala VR, Masrour-Roudsari
J, Babazadeh A. Vital role of chest CT in diagnosis of coronavirus
disease 2019 (COVID-19). Caspian journal of internal medicine. 2020
;11(3):244.
3. Afshar ZM, Ebrahimpour S, Javanian M, Koppolu V, Vasigala VK,
Hasanpour AH, et al. Coronavirus disease 2019 (COVID-19), MERS and SARS:
Similarity and difference. Journal of Acute Disease. 2020 1;9(5):194.
4. Ma Q, Qi D, Deng X, Yuan G, Tian W, Cui Y, et al. Corticosteroid
therapy for patients with severe novel Coronavirus disease 2019. Eur Rev
Med Pharmacol Sci. 2020;24(15):8194-201.
5. Ye Q, Wang B, Mao J. Cytokine storm in COVID-19 and treatment.
Journal of Infection. 2020.
6. Huang R, Zhu C, Wang J, Xue L, Li C, Yan X, et al. Corticosteroid
therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19
patients. European journal of pharmacology. 2020;889:173556.
7. Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: evidence and
hope during the pandemic. Jama. 2020;324(13):1292-5.
8. Matthay MA, Wick KD. Corticosteroids, COVID-19 pneumonia, and acute
respiratory distress syndrome. The Journal of clinical investigation.
2020;130(12).
9. Zhou Z-G, Xie S-m, Zhang J, Zheng F, Liu J-H, Cai C-L, et al.
Short-term moderate-dose corticosteroid plus immunoglobulin effectively
reverses COVID-19 patients who have failed low-dose therapy. 2020.
10. Ma Y, Zeng H, Zhan Z, Lu H, Zeng Z, He C, et al. Corticosteroid use
in the treatment of COVID-19: a multicenter retrospective study in
hunan, China. Frontiers in pharmacology. 2020;11:1198.
11. Li N, Jie Z. The application of corticosteroids in COVID-19: A
two-edged sword. Journal of Translational Internal Medicine.
2020;8(2):66-70.
12. Mattos-Silva P, Felix NS, Silva PL, Robba C, Battaglini D, Pelosi P,
et al. Pros and cons of corticosteroid therapy for COVID-19 patients.
Respiratory physiology & neurobiology. 2020;280:103492.
13. Hu Z, Lv Y, Xu C, Sun W, Chen W, Peng Z, et al. Clinical use of
short-course and low-dose corticosteroids in patients with non-severe
COVID-19 during pneumonia progression. Frontiers in public health.
2020;8:355.
14. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential
benefits of precise corticosteroids therapy for severe 2019-nCoV
pneumonia. Signal transduction and targeted therapy. 2020;5(1):1-3.
15. Cusacovich I, Marcos M, Ybarra-Falcón C, Iglesias-Echevarria C,
Lopez-Veloso M, Barraza-Vengoechea J, et al. Corticosteroid pulses for
hospitalized patients with COVID-19: Effects on mortality. 2020.
16. Demirbaş A, Elmas ÖF, Atasoy M, Türsen Ü, Lotti T. A case of
erythema multiforme major in a patient with COVID 19: The role of
corticosteroid treatment. Dermatologic therapy. 2020.
17. Touisserkani SK, Ayatollahi A. Oral corticosteroid relieves
post-COVID-19 anosmia in a 35-year-old patient. Case Reports in
Otolaryngology. 2020;2020.
18. Hu Z, Chen W, Liang W, Xu C, Sun W, Yi Y. Severe exacerbation of
immune thrombocytopenia and COVID-19: the favorable response to
corticosteroid-based therapy—a case report. Annals of Hematology.
2020:1.
19. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al.
Effect of hydrocortisone on mortality and organ support in patients with
severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized
clinical trial. Jama. 2020;324(13):1317-29.
20. Johnson RM, Vinetz JM. Dexamethasone in the management of covid-19.
British Medical Journal Publishing Group; 2020.
21. Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, et al. Impact of
corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV,
or MERS-CoV infection: a systematic review and meta-analysis. Leukemia.
2020:1-9.
22. Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in
the management of COVID-19: A systemic review and a Clinician’s
perspective. Diabetes & Metabolic Syndrome: Clinical Research &
Reviews. 2020;14(5):971-8.
23. Group RC. Dexamethasone in hospitalized patients with
Covid-19—preliminary report. New England Journal of Medicine. 2020.
24. Seo SJ, Priefer R. Dexamethasone Mechanism in Inflammatory Immune
Mediated Disease and its Application in Treating 2019 Coronavirus
Disease (COVID-19). Medical Research Archives. 2020;8(12).
25. Theoharides T, Conti P. Dexamethasone for COVID-19? Not so fast. J
Biol Regul Homeost Agents. 2020;34(3):10.23812.
26. Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T.
Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia:
Report of three cases. Journal of Infection and Chemotherapy. 2020.
27. Fadel R, Morrison A, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et
al. Early Short Course Corticosteroids in Hospitalized Patients with
COVID-19. medRxiv. 2020.
28. Fernández‐Ruiz M, López‐Medrano F, Pérez‐Jacoiste Asín MA, Maestro
de la Calle G, Bueno H, Caro‐Teller JM, et al. Tocilizumab for the
treatment of adult patients with severe COVID‐19 pneumonia: A
single‐center cohort study. Journal of medical virology. 2020.
29. Heesom L, Rehnberg L, Nasim-Mohi M, Jackson AI, Celinski M,
Dushianthan A, et al. Procalcitonin as an antibiotic stewardship tool in
COVID-19 patients in the intensive care unit. Journal of Global
Antimicrobial Resistance. 2020;22:782-4.
30. Liu F, Ji C, Luo J, Wu W, Zhang J, Zhong Z, et al. Clinical
characteristics and corticosteroids application of different clinical
types in patients with corona virus disease 2019. Scientific Reports.
2020;10(1):1-9.
31. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC,
et al. effect of dexamethasone on days alive and ventilator-free in
patients with moderate or severe acute respiratory distress syndrome and
COVID-19: the CoDEX randomized clinical trial. Jama.
2020;324(13):1307-16.
32. Liu Z, Li X, Fan G, Zhou F, Wang Y, Huang L, et al. Low-to-moderate
dose corticosteroids treatment in hospitalized adults with COVID-19.
Clinical Microbiology and Infection. 2020.
33. Yang J-W, Yang L, Luo R-G, Xu J-F. Corticosteroid administration for
viral pneumonia: COVID-19 and beyond. Clinical Microbiology and
Infection. 2020.
34. Bani-Sadr F, Hentzien M, Pascard M, N’Guyen Y, Servettaz A,
Andreoletti L, et al. Corticosteroid therapy for patients with COVID-19
pneumonia: a before–after study. International Journal of Antimicrobial
Agents. 2020;56(2):106077.
35. Chen Y, Li L. Influence of Corticosteroid Dose on Viral Shedding
Duration in Patients With COVID-19. Clinical Infectious Diseases. 2020.
36. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids
for 2019-nCoV pneumonia. Lancet (London, England). 2020;395(10225):683.
37. Lai Q, Spoletini G, Bianco G, Graceffa D, Agnes S, Rossi M, et al.
SARS‐CoV2 and immunosuppression: a double‐edged sword. Transplant
Infectious Disease. 2020:e13404.
38. Fraser J, Mousley J, Testro A, Smibert OC, Koshy AN, editors.
Clinical presentation, treatment, and mortality rate in liver transplant
recipients with coronavirus disease 2019: a systematic review and
quantitative analysis. Transplantation proceedings; 2020: Elsevier.
39. Krasner AS. Glucocorticoid-induced adrenal insufficiency. Jama.
1999;282(7):671-6.
40. Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, et al.
Dexamethasone therapy in COVID‐19 patients: implications and guidance
for the management of blood glucose in people with and without diabetes.
Diabetic Medicine. 2020;38(1):e14378.
41. Zhang B, Zhang S. Corticosteroid-induced osteonecrosis in COVID-19:
a call for caution. J Bone Miner Res. 2020;35(9):1828-9.
42. Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W,
Rochwerg B, et al. Efficacy and safety of corticosteroids in COVID-19
based on evidence for COVID-19, other coronavirus infections, influenza,
community-acquired pneumonia and acute respiratory distress syndrome: a
systematic review and meta-analysis. CMAJ. 2020.
43. Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P,
Krause R, et al. COVID-19 associated pulmonary aspergillosis
(CAPA)—from immunology to treatment. Journal of Fungi. 2020;6(2):91.
44. Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With
COVID-19. Cureus. 2020;12(9).
45. Hu W, Li C, Xu Y, Qi Y, Zhang Z, Li M, et al. Disorders of sodium
balance and its clinical implications in COVID-19 patients: a
multicenter retrospective study. Internal and Emergency Medicine.
2020:1-10.
46. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L,
et al. COVID-19 pneumonia: different respiratory treatments for
different phenotypes? : Springer; 2020.
47. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P,
Sebastian T, et al. Venous and arterial thromboembolic complications in
COVID-19 patients admitted to an academic hospital in Milan, Italy.
Thrombosis research. 2020.
48. McIntosh JJ. Corticosteroid guidance for pregnancy during COVID-19
pandemic. American journal of perinatology. 2020;37(8):809.
49. Liao S-Y, Petrache I, Fingerlin TE, Maier LA. Association of inhaled
and systemic corticosteroid use with Coronavirus Disease 2019 (COVID-19)
test positivity in patients with chronic pulmonary diseases. Respiratory
medicine. 2020:106275.
50. Inoue H, Jinno M, Ohta S, Kishino Y, Kawahara T, Mikuni H, et al.
Combination treatment of short-course systemic corticosteroid and
favipiravir in a successfully treated case of critically ill COVID-19
pneumonia with COPD. Respiratory medicine case reports. 2020;31:101200.
51. Williams DM. Clinical pharmacology of corticosteroids. Respiratory
care. 2018;63(6):655-70.
52. Maraka S, Kennel KA. Bisphosphonates for the prevention and
treatment of osteoporosis. Bmj. 2015;351:h3783.
53. Tang C, Wang Y, Lv H, Guan Z, Gu J. Caution against
corticosteroid-based COVID-19 treatment. The Lancet. 2020.
54. Kow CS, Hasan SS. Corticosteroid-related In-Hospital Hyperglycemia:
Does It Negate Mortality Benefits in Coronavirus Disease 2019? Clinical
Infectious Diseases. 2020.
55. Lester M, Sahin A, Pasyar A. The use of dexamethasone in the
treatment of COVID-19. Annals of Medicine and Surgery. 2020.
56. Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid
treatment of patients with coronavirus disease 2019 (COVID‐19). Medical
Journal of Australia. 2020;212(9):416-20.
57. Shuto H, Komiya K, Yamasue M, Uchida S, Ogura T, Mukae H, et al. A
systematic review of corticosteroid treatment for noncritically ill
patients with COVID-19. Scientific reports. 2020;10(1):1-8.